These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33786273)

  • 21. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
    Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
    Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Kobayashi K; Toyoda M; Hatori N; Saito N; Kanaoka T; Sakai H; Furuki T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
    Diabetes Technol Ther; 2021 Feb; 23(2):110-119. PubMed ID: 32721227
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience.
    Tumminia A; Graziano M; Vinciguerra F; Lomonaco A; Frittita L
    Prim Care Diabetes; 2021 Apr; 15(2):283-288. PubMed ID: 33129749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
    Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
    Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis.
    Mauricio D; Gourdy P; Bonadonna RC; Freemantle N; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M; Müller-Wieland D
    Diabetes Ther; 2021 Apr; 12(4):1159-1174. PubMed ID: 33751403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
    Bai Y; Jin J; Zhou W; Zhang S; Xu J
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
    Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
    J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial.
    Min KW; Ku BJ; Lee JH; Kim MS; Ahn KJ; Lee MK; Kokubo S; Yoshida S; Cho HJ; Cha BS
    Diabetes Metab J; 2017 Apr; 41(2):135-145. PubMed ID: 28447440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
    Shingaki T; Taki K; Koyanagi M; Nagaoka S; Yoshizawa K; Oki N; Yoshikawa A; Imaoka T
    Curr Med Res Opin; 2020 Jun; 36(6):947-958. PubMed ID: 32271092
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.
    Yano K; Seko Y; Takahashi A; Okishio S; Kataoka S; Takemura M; Okuda K; Mizuno N; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Okanoue T; Itoh Y
    Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32041289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.